WHO ICTRP trial
Effect of cabergoline in treatment of uterine myoma
IRCT20170917036227N4 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20170917036227N4 |
|---|---|
| Public title | Effect of cabergoline in treatment of uterine myoma |
| Scientific title | Effect of cabergoline on myoma size and uterine bleeding in women with myomas attending to Arash Hospital |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | leiomyoma. Leiomyoma of uterus |
| Interventions | Intervention 1: Intervention group: 0.5 mg cabergoline tablet (weekly orally, 0.5mg Dostinex tablets per week made in Italy with a generic code of 00562 for 3 months). Intervention 2: Control group: Placebo (composed of sugar and starch, in… |
| Registration date | Jun 2, 2019 |
| Target size | 50 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: